Abstract
Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Current Gene Therapy
Title:Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies
Volume: 13 Issue: 4
Author(s): Andrew M. Scharenberg, Philippe Duchateau and Julianne Smith
Affiliation:
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Abstract: Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Export Options
About this article
Cite this article as:
Scharenberg M. Andrew, Duchateau Philippe and Smith Julianne, Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies, Current Gene Therapy 2013; 13 (4) . https://dx.doi.org/10.2174/15665232113139990026
DOI https://dx.doi.org/10.2174/15665232113139990026 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect on the Intestine of Some Fungal Toxins: The Trichothecenes
Current Immunology Reviews (Discontinued) Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Protein & Peptide Science Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Genomics and Natural Products: Role of Bioinformatics and Recent Patents
Recent Patents on Biotechnology “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism The Endocrine System and Sarcopenia: Potential Therapeutic Benefits
Current Aging Science Machine Intelligence Techniques for the Identification and Diagnosis of COVID-19
Current Medicinal Chemistry Targeting Cystathionine Beta-Synthase Misfolding in Homocystinuria by Small Ligands: State of the Art and Future Directions
Current Drug Targets The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Daclizumab: A Potential Asthma Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Microdialysis in Drug Discovery
Current Drug Discovery Technologies Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology